No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BTCY Biotricity
- 0.7600
- -0.0390-4.88%
Close Jul 2 16:00 ET
- 0.7800
- +0.0200+2.63%
Post 19:39 ET
16.45MMarket Cap-457P/E (TTM)
0.8470High0.7506Low72.12KVolume0.8001Open0.7990Pre Close55.71KTurnover0.37%Turnover RatioLossP/E (Static)21.65MShares3.750052wk High-0.52P/B14.80MFloat Cap0.700752wk Low--Dividend TTM19.48MShs Float31.8000Historical High--Div YieldTTM12.07%Amplitude0.7000Historical Low0.7720Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biotricity | 10-K/A: Annual report (Amendment)
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Democratizing cardiac health with convenient, rapid, and reliable results REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) co
Earnings Call: Biotricity Reports Growth and Expansion in FY 2024
Biotricity, Inc. (BTCY) Q4 2024 Earnings Call Transcript
Biotricity, Inc. (BTCY) Q4 2024 Earnings Call Transcript
Biotricity GAAP EPS of -$0.47, Revenue of $3.2M In-line
Express News | Biotricity Q4 Revenue $3.2M, Up 15.9% YoY, EPS $(0.47)
Comments
$Biotricity(BTCY.US$ • Biotricity's fiscal year 2024 revenue rose to $12.06 million, a 25% increase, with Q4 revenue up 15.9% to $3.2 million.
• Gross profit for the quarter was $2.3 million, a 48% year-over-year increase, with a gross margin of 71.5%.
• Operating expenses decreased by 17%, and the company is aiming for EBITDA neutrality and profitability soon.
• Strategic initiatives included the launch of Biocore Pro and HeartSecure, partnerships with industry leaders, and ex...
• Gross profit for the quarter was $2.3 million, a 48% year-over-year increase, with a gross margin of 71.5%.
• Operating expenses decreased by 17%, and the company is aiming for EBITDA neutrality and profitability soon.
• Strategic initiatives included the launch of Biocore Pro and HeartSecure, partnerships with industry leaders, and ex...
1
$Biotricity(BTCY.US$ Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Accesswire· 1 min ago
Democratizing cardiac health with convenient, rapid, and reliable results
Accesswire· 1 min ago
Democratizing cardiac health with convenient, rapid, and reliable results
$Biotricity(BTCY.US$
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Biotricity, a leader in Technology-as-a-Service (TaaS) for healthcare, has launched HeartSecure, a direct-to-consumer heart health screening service.
Heart disease is a major global health issue, with cardiovascular disease causing one death every 1.5...
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Biotricity, a leader in Technology-as-a-Service (TaaS) for healthcare, has launched HeartSecure, a direct-to-consumer heart health screening service.
Heart disease is a major global health issue, with cardiovascular disease causing one death every 1.5...
$Biotricity(BTCY.US$ Not even a great improvement YoY in earnings can get any volume! Hehehe! Now thats some pathetic interest![]()
$Biotricity(BTCY.US$ Biotricity Provides Year-End Guidance With Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Accesswire·
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnost...
Accesswire·
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnost...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg